Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.62 HKD | -0.71% | -.--% | -.--% |
04-01 | Venus Medtech Trims Loss in 2023 as Revenue Grows Nearly 21% | MT |
03-28 | Venus Medtech Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- The company's share price in relation to its net book value makes it look relatively cheap.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- With an enterprise value anticipated at 3.64 times the sales for the current fiscal year, the company turns out to be overvalued.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- Revenue estimates are regularly revised downwards for the current and coming years.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-.--% | 314M | B | ||
+13.47% | 128B | A- | ||
-8.41% | 10.65B | A- | ||
+0.91% | 8.82B | C | ||
+19.00% | 7.19B | C | ||
+23.15% | 4.99B | B+ | ||
+7.14% | 3.4B | C- | ||
+0.45% | 3.03B | B- | ||
-8.73% | 2.14B | - | - | |
-10.15% | 2B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
- Stock Market
- Equities
- 2500 Stock
- Ratings Venus Medtech (Hangzhou) Inc.